Abiopharma

HARROW, INC. (HROW)

Symbol	HROW
Name	HARROW, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	1A BURTON HILLS BLVD.,SUITE 200, NASHVILLE, Tennessee, 37215, United States
Telephone	+1 615 - 733-4730
Fax	—
Email	—
Website	https://www.harrow.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001360214
Description	Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits. Additional info from NASDAQ: Arrow Electronics is a global distributor of electronics, connecting suppliers of semiconductors, components, and IT solutions to more than 180,000 small and midsize customers in 85 countries. Arrow is the second- largest semiconductor distributor in the world, and the largest for North American chip distribution, partnering with a third of global chipmakers. Additional info from NASDAQ: Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.

2026-08-06 11:00

Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

2026-07-27 11:00

Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

2026-07-20 12:00

Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

2026-07-20 11:00

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

2026-07-01 11:00

Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow

2026-07-01 11:00

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

2026-06-22 23:51

Director Sternberg Perry J. 🟢 acquired 5.2K shares (1 derivative) of HARROW, INC. (HROW) Transaction Date: Jun 18, 2026 | Filing ID: 029659

2026-06-22 23:51

Director SILVERNAIL LAUREN P 🟢 acquired 5.2K shares (1 derivative) of HARROW, INC. (HROW) Transaction Date: Jun 18, 2026 | Filing ID: 029658

2026-06-22 23:50

Director Graves Adrienne L 🟢 acquired 5.2K shares (1 derivative) of HARROW, INC. (HROW) Transaction Date: Jun 18, 2026 | Filing ID: 029657

2026-06-22 11:30

(99% Neutral) HARROW, INC. (HROW) Announces Regulatory Update

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07368595	Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With…	Phase4	Dry Eye Disease (DED)	Not_Yet_Recruiting	2026-09-01	2027-06-01	ClinicalTrials.gov
NCT07224529	Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysf…	Phase4	Meibomian Gland Dysfunction (MGD)	Recruiting	2026-06-01	2027-02-01	ClinicalTrials.gov
NCT07566975	Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of …	—	Dry Eye	Recruiting	2026-03-31	2026-11-30	ClinicalTrials.gov
NCT07456826	Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3…	Phase4	Diabetic Macular Edema (DME)	Enrolling_By_Invitation	2026-03-31	2026-08-01	ClinicalTrials.gov
NCT05934253	The Effects of Low Viscosity Chloroprocaine Ophthalmic Gel 3% on the Bactericid…	Phase4	Antiseptic	Completed	2023-07-15	2024-02-15	ClinicalTrials.gov
NCT07588074	Tolerability Comparison of Flarex to Lotemax SM	Phase4	Ocular Inflammation	Completed	2021-05-01	2021-06-30	ClinicalTrials.gov
NCT02372552	Microwave Coagulation Using CROMA Electrosurgical System	Na	Polyp of Large Intestine	Completed	2015-08-01	2016-06-01	ClinicalTrials.gov
NCT00157066	Effects of Vitamin D Supplementation on Antimycobacterial Immunity	Na	Tuberculosis	Completed	2002-12-01	2006-09-01	ClinicalTrials.gov

Total clinical trials: 8

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Vevye(Cyclosporine 0.1% Ophthalmic Solution)	Other	Phase PHASE4	Meibomian Gland Dysfunction (MGD)	RECRUITING	NCT07224529
Cyclosporine emulsion	Other	Phase PHASE4	Dry Eye Disease (DED)	NOT_YET_RECRUITING	NCT07368595
Vevye®	Other	Phase PHASE4	Dry Eye Disease (DED)	NOT_YET_RECRUITING	NCT07368595
Loteprednol Etabonate Ophthalmic Gel 0.38%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Fluorometholone Acetate Ophthalmic Suspension 0.1%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Loteprednol Etabonate Ophthalmic Gel 0.38%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Fluorometholone Acetate Ophthalmic Suspension 0.1%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Loteprednol Etabonate Ophthalmic Gel 0.38%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Fluorometholone Acetate Ophthalmic Suspension 0.1%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Loteprednol Etabonate Ophthalmic Gel 0.38%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Fluorometholone Acetate Ophthalmic Suspension 0.1%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Loteprednol Etabonate Ophthalmic Gel 0.38%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Fluorometholone Acetate Ophthalmic Suspension 0.1%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Loteprednol Etabonate Ophthalmic Gel 0.38%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Fluorometholone Acetate Ophthalmic Suspension 0.1%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Loteprednol Etabonate Ophthalmic Gel 0.38%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Fluorometholone Acetate Ophthalmic Suspension 0.1%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Loteprednol Etabonate Ophthalmic Gel 0.38%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Fluorometholone Acetate Ophthalmic Suspension 0.1%	Other	Phase PHASE4	Ocular Inflammation	COMPLETED	NCT07588074
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Cyclosporine ophthalmic solution 0.1%	Other	Preclinical	Dry Eye	RECRUITING	NCT07566975
Ergocalciferol	Other	Approved	Tuberculosis	COMPLETED	NCT00157066
Ergocalciferol	Other	Approved	Tuberculosis	COMPLETED	NCT00157066
CROMA	Other	Approved	Polyp of Large Intestine	COMPLETED	NCT02372552
Chloroprocaine ophthalmic gel 3%	Other	Phase PHASE4	Antiseptic	COMPLETED	NCT05934253
Cyclosporine emulsion	Other	Phase PHASE4	Dry Eye Disease (DED)	NOT_YET_RECRUITING	NCT07368595
Vevye®	Other	Phase PHASE4	Dry Eye Disease (DED)	NOT_YET_RECRUITING	NCT07368595
Lidocaine Hydrochloride Injection 2%	Other	Phase PHASE4	Diabetic Macular Edema (DME)	ENROLLING_BY_INVITATION	NCT07456826
Proparacaine Hydrochloride Ophthalmic Solution 0.5%	Other	Phase PHASE4	Diabetic Macular Edema (DME)	ENROLLING_BY_INVITATION	NCT07456826
Sham Subconjunctival Injection	Other	Phase PHASE4	Diabetic Macular Edema (DME)	ENROLLING_BY_INVITATION	NCT07456826
Chloroprocaine Ophthalmic Gel 3% (IHEEZO)	Other	Phase PHASE4	Diabetic Macular Edema (DME)	ENROLLING_BY_INVITATION	NCT07456826
CROMA	DEVICE	Approved	Polyp of Large Intestine	COMPLETED	NCT02372552
Lidocaine Hydrochloride Injection 2%	DRUG	Phase PHASE4	Diabetic Macular Edema (DME)	RECRUITING	NCT07456826
Proparacaine Hydrochloride Ophthalmic Solution 0.5%	DRUG	Phase PHASE4	Diabetic Macular Edema (DME)	RECRUITING	NCT07456826
Sham Subconjunctival Injection	PROCEDURE	Phase PHASE4	Diabetic Macular Edema (DME)	RECRUITING	NCT07456826
Chloroprocaine Ophthalmic Gel 3% (IHEEZO)	DRUG	Phase PHASE4	Diabetic Macular Edema (DME)	RECRUITING	NCT07456826
Cyclosporine emulsion	DRUG	Phase PHASE4	Dry Eye Disease (DED)	NOT_YET_RECRUITING	NCT07368595
Vevye®	DRUG	Phase PHASE4	Dry Eye Disease (DED)	NOT_YET_RECRUITING	NCT07368595
Vevye(Cyclosporine 0.1% Ophthalmic Solution)	DRUG	Phase PHASE4	Meibomian Gland Dysfunction (MGD)	NOT_YET_RECRUITING	NCT07224529
Chloroprocaine ophthalmic gel 3%	DRUG	Phase PHASE4	Antiseptic	COMPLETED	NCT05934253

Total products: 55